Therapeutic efficiency of seretide plus montelukast on patients with asthma and effect on the serum IL-6 and TNF-α
10.3760/cma.j.issn.1008-6706.2009.s1.003
- VernacularTitle:孟鲁司特联合沙美特罗替卡松粉吸入剂对哮喘的疗效及对血清IL-6、TNF-α的影响
- Author:
Liming LUO
;
Wenqing CHEN
;
Biao HUANG
;
Zhihe CHEN
;
Guochun HUANG
- Publication Type:Journal Article
- Keywords:
Asthma;
Montelukast;
Salmetero;
Fluticasone;
Respiratory function tests;
Tumor necrosis factor-alpha;
Interleukin-6
- From:
Chinese Journal of Primary Medicine and Pharmacy
2009;16(z1):4-5
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of seretide plus montelukast on clinical symptoms、pulmonary functions and the serum IL-6 and TNF-α of patients with asthma.Methods 73 cases patients with asthma were randomly divided into seretide group and seretide plus montelukast group and were treated respectively for two weeks.The clinical symptoms,lung functions and serum IL-6,TNF-α contents of patients were measured respectively before treatment and after two weeks treatment.Results After two weeks treatment,the clinical symptom scores、FEV1.0、FVC and PEFR of two groups had significantly changed than that before treatment(P<0.05);Each index was further compared after treatment,and it was found that two groups had significant differernces statistically (P<0.05),these showed that combination of seretide and montelukast could significantly enhance the therapeutic effect.After treatment,the TNF-α and IL-6 contents in the peripheral blood of seretide group and seretide plus montelukast group had both significantly reducted (P<0.05 or P<0.01);The TNF-α and IL-6 contents of seretide plus montelukast group had reduced more significantly than that of the seretide group(P<0.05).Conclusion The seretide plus montelukast group could improve the clinical symptoms and pulmonary function of patients with asthma,and the action mechanism might be related to lower the serum IL-6 and TNF-α contents.
